Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Zhonghua Gan Zang Bing Za Zhi ; 29(10): 1006-1013, 2021 Oct 20.
Article in Chinese | MEDLINE | ID: mdl-34814397

ABSTRACT

Objective: Hepatocellular carcinoma (HCC) is the fourth most dominant cancer in the world and the second leading cause of cancer-related deaths in the China. With the increase in the incidence of metabolic syndrome (MS) in the population, the correlation between MS and HCC has gradually been recognized. MS manifests as non-alcoholic fatty liver disease (shortly known as NAFLD) in the liver. A large number of research results has shown that the development of fatty liver is closely related to the occurrence of HCC, in which lipid metabolism plays a key regulatory role, and lipid metabolism is regulated by fatty acid binding protein (FABP). This study signifies the lipid metabolism analysis and the key FABP expression conditions in HCC. Methods: Data of patients who were first diagnosed with primary HCC between January 2016 to July 2019 were collected, and were divided into two groups according to the etiology, namely the viral and non-viral hepatitis-related HCC group. The relationship between MS-related factors and HCC was analyzed by t-test and chi square test. The expressions of FABP1, FABP4 and FABP5 were detected in cancer and adjacent tissues by immunohistochemistry, and the expressions of FABP1, FABP4 and FABP5 in HCC with fatty liver were detected by immunofluorescence. Finally, the expressional characteristics of the above-mentioned FABPs in HCC patients were analyzed with different clinicopathological features. Results: There were statistically significant differences in the rate of abnormal lipid metabolism and the number of abnormalities in MS-related factors between the viral and non-viral hepatitis-related HCC group. FABP1, FABP4, and FABP5 expression in HCC tissues were lower than the corresponding adjacent tumor tissues. Compared with simple HCC, FABP1, FABP4, FABP5 expression were increased in HCC tissues with steatosis, and the expression of FABP was closely related to the clinical characteristics of patients. Conclusion: Abnormal lipid metabolism is closely related to non-viral hepatitis-related HCC. The expression of lipid metabolism regulatory proteins FABP1, FABP4, and FABP5 are down-regulated in HCC tissues, but up-regulated in HCC with fatty liver, suggesting that the relationship between MS, especially dyslipidemia, and HCC should be paid attention to in clinical practice for early intervention. FABP1, FABP4, FABP5 may regulate HCC occurrence and development.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Fatty Acid-Binding Proteins/metabolism , Humans , Lipid Metabolism
2.
Zhonghua Gan Zang Bing Za Zhi ; 27(3): 219-222, 2019 Mar 20.
Article in Chinese | MEDLINE | ID: mdl-30929341

ABSTRACT

The incidence of metabolic syndrome gradually multiplied with the change of dietary structure of high fat- high sugar in the population, bringing it as independent risk factors for tumors. Liver is an important organ of lipid metabolism. The main manifestations of metabolic syndrome are obesity and abnormal lipid metabolism, which are closely related to hepatocellular carcinoma occurrence. MicroRNA (miRNA) is an endogenous non-coding RNA that participates in the post-transcriptional regulation of target genes by binding to the 3'-UTR of mRNA. Research studies have found that abnormal miRNA expression can influence the pathogenesis of hepatocellular carcinoma via regulating lipid metabolism-related proteins in the liver. This article reviews and discusses the characteristics and pathogenesis of lipid metabolism disorder in hepatocellular carcinoma, and the mechanism by which miRNA regulates the occurrence and development of hepatocellular carcinoma through lipid metabolism-related proteins. Furthermore, it also provides a reliable theoretical foundation for the study of the pathogenesis of hepatocellular carcinoma.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Gene Expression Regulation, Neoplastic , Humans , Lipid Metabolism , MicroRNAs
3.
Neuroscience ; 300: 75-84, 2015 Aug 06.
Article in English | MEDLINE | ID: mdl-25987199

ABSTRACT

Our previous study has proved that glucagon-like peptide-1 (GLP-1), which is developed to treat type 2 diabetes, has a significant effect on neuroprotection against advanced glycation end product (AGE)-induced neuronal insult in vitro models of diabetes-related Alzheimer's disease (AD). However, the molecular mechanisms remain to be elucidated and it is not clear whether GLP-1 receptor mediates the down-regulation effects on AGE-induced AD-like changes in vivo. This study aims to explore the effect and mechanisms of GLP-1 receptor agonists (GLP-1RA) against the AGE-dependent signaling pathway both in vitro and in vivo. In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1µg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3ß (GSK-3ß) to reverse tau hyperphosphorylation directly. Collectively, our results suggest that GLP-1RA protects neurons against AGE-induced tau hyperphosphorylation via regulating GSK-3ß and PGC-1α two cooperative signaling pathways.


Subject(s)
Glucagon-Like Peptide-1 Receptor/agonists , Mitochondria/drug effects , Neuroprotective Agents/pharmacology , tau Proteins/metabolism , Animals , Glucagon-Like Peptide 1/metabolism , Glucagon-Like Peptide-1 Receptor/metabolism , Glycation End Products, Advanced/toxicity , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Male , Membrane Potential, Mitochondrial/physiology , Mice, Inbred ICR , Mitochondria/pathology , Mitochondria/physiology , Neurons/drug effects , Neurons/pathology , Neurons/physiology , Organelle Biogenesis , PC12 Cells , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Phosphorylation/drug effects , Phosphorylation/physiology , Random Allocation , Rats , Transcription Factors/metabolism
4.
Neuroscience ; 256: 137-46, 2014 Jan 03.
Article in English | MEDLINE | ID: mdl-24183963

ABSTRACT

We have previously demonstrated that glucagon-like peptide-1 (GLP-1) receptor agonist ameliorated neurodegenerative changes in rat models of diabetes-related Alzheimer's disease (AD), and protected neurons from glucose toxicity in vitro. Herein, we investigated the effects of GLP-1 receptor mediates on cell toxicity and tau hyperphosphorylation induced by advanced glycation end products (AGEs), which are associated with glucose toxicity, and the molecular mechanism in PC12 cells and the primary hippocampal neurons. Our study demonstrated that the similar protection effects of GLP-1 existed in PC12 cells treated with glucose-bovine serum albumin (BSA) in hyperglycemic conditions or with glycoaldehyde-BSA alone. Additionally, glucose-BSA alone did not induce significant cytotoxicity in PC12 cells, but resulted in tau hyperphosphorylation in primary hippocampal neurons in 24h. And we found that GLP-1 could reduce cell tau phosphorylation induced by high glucose or glucose-BSA. Furthermore, our data in the present study suggested that GLP-1 regulated tau phosphorylation induced by AGEs through a signaling pathway involving glycogen synthase kinase 3ß (GSK-3ß), similarly to the GSK-3ß inhibitor, lithium chloride. Our findings suggest that GLP-1 can protect neurons from diabetes-associated AGE insults in vitro, and provide new evidence for a potential therapeutic value of GLP-1 receptor agonist in the treatment of AD especially diabetes-related AD.


Subject(s)
Glucagon-Like Peptide 1/pharmacology , Glycation End Products, Advanced/toxicity , Hippocampus/cytology , Neurons/drug effects , Neuroprotective Agents/pharmacology , tau Proteins/metabolism , Androstadienes/pharmacology , Animals , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Glucose/toxicity , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Phosphorylation/drug effects , Rats , Rats, Wistar , Serine/metabolism , Serum Albumin, Bovine/toxicity , Wortmannin
SELECTION OF CITATIONS
SEARCH DETAIL
...